|
|
SUSAN DENTZER: It's been clear for months that prescription drug costs
and coverage would be big issues this election year. So after the House
of Representatives voted last month to expand seniors' coverage for
prescription drugs, Senators said this week they also felt compelled
to act.
SEN.
EDWARD KENNEDY: Every single day that we fail to enact a prescription
drug benefit program that is affordable, accessible, available to seniors,
we are violating that solemn commitment and promise to our seniors --
every day, every day, today, tomorrow.
SUSAN DENTZER: But there's broad disagreement on how to expand drug
coverage under Medicare. So today Senators started debate on a provision
to lower drug costs by allowing more generic drugs onto the market faster.
Along with Democrat Chuck Schumer of New York, Republican John McCain
of Arizona is a lead sponsor.
REP.
JOHN MCCAIN: There are people today, as we speak, who are making a choice
between their health and their income. Madame President, that's wrong.
It's wrong.
SUSAN DENTZER: McCain and other proponents say the bill would end several
of the legal maneuvers that pharmaceutical companies engage in to extend
their exclusive patent rights on brand-name drugs. Those measures can
delay the entry of cheaper generic alternatives into the market by up
to several years -- costing consumers and the government hundreds of
millions of dollars.
REP.
JOHN MCCAIN: And it's wrong when patent companies game the system by
doing things like bringing suits, which then delays the implementation.
It is wrong when patent drug companies actually pay generic drug companies
not to produce a particular prescription drug while they continue their
profits.
SUSAN DENTZER: Senators today debated whether other provisions should
be added to the generics bill. One, sponsored by Democrat Byron Dorgan
of North Dakota, would allow individuals -- as well as pharmacists and
health insurers -- to import lower-cost prescription drugs from Canada.
SENATOR BYRON DORGAN: This prescription drug is Celebrex, quite a remarkable
drug, I'm told. It is for pain for arthritis. It is sold both in the
United States and Canada and sold in a bottle that is almost identical,
with the exception that the one is sold in the United States has a blue
cap; the one that's sold in Canada has a white cap.
The
U.S. consumer is charged $2.20 per tablet; the Canadian consumer is
charged 79 cents per tablet. Same drug, same bottle, made by the same
company. The question that we should ask, it seems to me, as policymakers
is: Why should an American citizen have to go to Canada to get a fair
price on a prescription drug made in the United States?"
|
 |
|
SUSAN DENTZER: But Senators also made clear today that their most important
votes will come later this week or next -- and will deal with proposals
to broaden Medicare coverage for prescription drugs. As it stands, Medicare
for the most part pays only for drugs that beneficiaries take when they're
in the hospital. That leaves them relying on private insurance coverage
for the costs of outpatient drugs, or paying those bills out of pocket.
The broadest of three different proposals now under consideration in
the Senate is a Democratic plan sponsored by Senators Kennedy, Bob Graham
of Florida and Zell Miller of Georgia. Its estimated cost is $600 billion
over ten years. Senate Majority Leader Tom Daschle today called it the
best option.
REP.
TOM DASCHLE: I like it because it provides universal coverage. I like
it because it keeps the premiums low. It's a Medicare model, not a private
sector model. And I think if we're talking about a Medicare benefit,
it ought to be Medicare-administered.
SUSAN DENTZER: Next is the so-called "Tripartisan plan," backed
by conservative Democrats, some Republicans and the Senate's lone independent,
Jim Jeffords of Vermont. The estimated cost of the plan is about $370
billion over ten years.
SEN.
CHARLES GRASSLEY: Our bill - we call it the "21st Century Medicare
Act" -- has the best prescription drug benefit that we can buy
within our budget. It offers a great benefit with the lowest premium
of any of the pending comprehensive prescription drug proposals. The
average premium under the 21st century Medicare Act is just $24 a month.
SUSAN DENTZER: The third drug coverage measure is an all-Republican
plan; it would pay seniors' drug costs only after they reached so-called
"catastrophic" levels. Backers estimate the cost at about
$160 billion over 10 years.
SEN.
PHIL GRAMM: It is something that we can do now. I'm afraid that if we
fool around with proposals that when you fill in the blanks and project
the proposal out to 10 years, end up costing over a trillion dollars
each, that we'll end up with this Congress coming to an end without
having provided prescription drugs to people who need it the most.
SUSAN DENTZER: Senate budget rules will probably require 60 votes to
adopt a Medicare drug coverage plan, and Senators agreed today that
none of these proposals has yet garnered enough votes to pass.
|
 |